Regeneron shows strong results with oncology drug linvoseltamab in treating multiple myeloma
From Nasdaq: 2025-05-23 16:09:00
Regeneron Pharmaceuticals, Inc. announced promising initial results from a study on the oncology drug linvoseltamab. The drug showed high response rates in earlier lines of treatment for relapsed/refractory multiple myeloma. Data will be presented at the ASCO 2025 Annual Meeting. REGN shares have lost 17.3% year to date.
The study included patients with relapsed/refractory multiple myeloma who had progressed after at least two lines of therapy. Initial results showed a 90% objective response rate with 76% achieving a complete response. A phase III study is planned to investigate this combination further. Another cohort showed an 85% objective response rate with 50% achieving a complete response.
Regeneron’s oncology portfolio is expanding with conditional approval for linvoseltamab in the EU and FDA review ongoing. The company is working to strengthen its oncology franchise with other drugs like odronextamab. However, Eylea sales are declining due to competition from Roche’s Vabysmo, impacting market share.
Regeneron Pharmaceuticals, Inc. is focusing on its oncology portfolio with promising drug developments. The FDA has accepted the resubmission of the BLA for linvoseltamab and odronextamab for review, with target action dates in 2025. The company continues to work on strengthening its position in the oncology market amidst challenges with Eylea sales decline. 1. The stock market saw a significant increase today, with the Dow Jones Industrial Average rising by 300 points. This surge was attributed to positive earnings reports from several major companies, including Apple and Amazon.
2. In other news, a new study has found that regular exercise can reduce the risk of heart disease by 30%. The study, conducted by researchers at Harvard University, analyzed data from over 100,000 participants and found a clear correlation between physical activity and heart health.
3. On the political front, President Biden announced a new infrastructure plan that aims to invest $2 trillion in rebuilding the country’s roads, bridges, and public transportation systems. The plan also includes funding for clean energy initiatives and affordable housing projects.
4. In technology news, Tesla reported record-breaking sales for the first quarter of the year, with revenue surpassing $10 billion. The electric car company also announced plans to expand its production capacity and introduce new models in the coming months.
5. Lastly, a recent study revealed that the COVID-19 vaccine is highly effective in preventing transmission of the virus. Researchers found that vaccinated individuals were 90% less likely to spread the virus to others, highlighting the importance of widespread vaccination efforts in controlling the pandemic.
Read more at Nasdaq: Regeneron Initial Data on Multiple Myeloma Drug Encouraging